RxDoctor Payments Data

Sharmila Suri Mohanram, MD

Behavioral Neurology & Neuropsychiatry · Jefferson City, MONPI 1053690669

Payments from drug & device makers

$10,473in general payments, 2019–2025

Across 591 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boston Scientific$1K
  • Novartis$661
  • Acadia Pharmaceuticals Inc$554
  • Biogen$435
  • UCB, Inc.$417
  • plus $5K from 51 others

What the payments were for

  • Speaking & faculty fees$651%
  • Travel & lodging$7767%
  • Food & beverage$9,62492%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)137$2,027
Boston Scientific7$1,091
Novartis40$661
Acadia Pharmaceuticals Inc30$554
Biogen24$435
UCB, Inc.21$417
Sanofi23$402
Supernus Pharmaceuticals, Inc.36$350
EMD Serono, Inc.13$336
Amneal Pharmaceuticals LLC17$291
Pfizer24$271
Teva Pharmaceuticals USA, Inc.16$253
Lilly USA, LLC13$214
AstraZeneca(2 entities)5$196
Lundbeck LLC11$181
SK Life Science, Inc.11$178
Argenx US, Inc.9$172
Sunovion Pharmaceuticals Inc.11$147
Eisai Inc.8$143
Biohaven Pharmaceutical Holding Company Ltd.11$136
Bristol Myers Squibb7$129
Amgen7$126
Sumitomo Pharma America, Inc.8$126
Neurocrine Biosciences, Inc.6$121
Grifols USA, LLC5$99
Biohaven Pharmaceuticals, Inc.5$94
Abbott4$91
Medtronic(3 entities)5$85
Assertio Therapeutics, Inc.15$84
Impel Pharmaceuticals Inc.4$75
Neurelis, Inc.4$74
Acorda Therapeutics, Inc3$65
Adamas Pharmaceuticals, Inc.4$63
Ipsen Biopharmaceuticals, Inc4$63
Catalyst Pharmaceuticals, Inc.3$57
Almatica Pharma LLC2$55
Greenwich Biosciences, Inc.2$45
Zyla Life Sciences, Inc.5$43
Kyowa Kirin, Inc.3$40
Nevro Corp.2$40
Tanabe Pharma America, Inc.2$37
GE HealthCare2$35
Avion Pharmaceuticals2$34
Endo Pharmaceuticals Inc.2$34
Mallinckrodt Enterprises LLC2$33
Johnson & Johnson2$31
Aprecia Pharmaceuticals, LLC2$30
Bausch Health US, LLC1$29
Mallinckrodt Hospital Products Inc.2$28
Genentech USA, Inc.2$27
Alnylam Pharmaceuticals Inc.1$20
Otsuka America Pharmaceutical, Inc.1$20
Avanir Pharmaceuticals, Inc.1$19
Livanova USA, Inc.1$18
Vertical Pharmaceuticals, LLC1$17
Upsher-smith Laboratories LLC1$16
Banner Life Sciences, LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few behavioral neurology & neuropsychiatry providers in Missourito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$123,482
Medicare patients
701
Services billed
1,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate144$213,651
Emgality PenGalcanezumab-Gnlm198$184,771
UbrelvyUbrogepant155$178,241
Avonex (4 Pack)Interferon Beta-1a19$152,748
RebifInterferon Beta-1a/Albumin12$117,701
QuliptaAtogepant77$112,652
Aimovig AutoinjectorErenumab-Aooe128$111,356
NuplazidPimavanserin Tartrate11$94,009
BriviactBrivaracetam30$60,502
XcopriCenobamate38$44,418
Glatiramer Acetate14$32,087
Emgality SyringeGalcanezumab-Gnlm30$29,091
Lacosamide171$20,689
Carbidopa-Levodopa ErCarbidopa/Levodopa398$19,981
Carbamazepine ErCarbamazepine101$19,770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$2,027$290,893232 claims
PfizerNurtec Odt$271$213,651144 claims
BiogenAvonex (4 Pack)$435$152,74819 claims
EMD Serono, Inc.Rebif$336$117,70112 claims
UCB, Inc.Briviact, Nayzilam, Neupro$417$95,89574 claims
Acadia Pharmaceuticals IncNuplazid$554$94,00911 claims
SK Life Science, Inc.Xcopri$178$44,41838 claims
Sunovion Pharmaceuticals Inc.Aptiom$147$17,30613 claims
Eisai Inc.Fycompa$143$14,24913 claims
Amneal Pharmaceuticals LLCRytary$291$7,97517 claims
Upsher-smith Laboratories LLCTopiramate$16$4,302454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Missourion file to place this against a meaningful peer group, so we don't.

Other behavioral neurology & neuropsychiatry in Jefferson City

Where these figures come from

Is this you, or does something look wrong? →